Definium Therapeutics (DFTX) Cash from Operations (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Cash from Operations of 42631000.0 for Q1 2026, down 44.91% year-over-year from 77383932.19 in Q1 2025, and up 0.8% quarter-over-quarter from 42975000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Cash from Operations (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Cash from Operations for 6 consecutive years, with 42631000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 44.91% year-over-year to 42631000.0; the TTM figure through Mar 2026 stood at 144772000.0 (down 57.45% YoY), while the FY2025 annual figure was 131560000.0, down 66.26% from the prior year.
- Cash from Operations advanced to 42631000.0 in Q1 2026 per DFTX's latest filing, from 42975000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 9297000.0 in Q3 2022 and bottomed at 42975000.0 in Q4 2025.
- Historically, Cash from Operations has averaged 21636705.88 across 5 years, with a median of 17191000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 44.6% — and 2023, when it sank 78.83%.
- Definium Therapeutics' Cash from Operations stood at 12849000.0 in 2022, then slumped by 60.04% to 20563000.0 in 2023, then decreased by 23.28% to 25351000.0 in 2024, then slumped by 69.52% to 42975000.0 in 2025, then increased by 0.8% to 42631000.0 in 2026.
- Business Quant data shows DFTX's Cash from Operations at 42631000.0 in Q1 2026, 42975000.0 in Q4 2025, and 29567000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | -52.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -52.78 Mn |
| Mar 31, 2026 | -42.63 Mn |
| Dec 31, 2025 | -42.98 Mn |
| Sep 30, 2025 | -29.57 Mn |
| Jun 30, 2025 | -29.60 Mn |
| Mar 31, 2025 | -29.42 Mn |
| Dec 31, 2024 | -25.35 Mn |
| Sep 30, 2024 | -17.19 Mn |
| Jun 30, 2024 | -19.99 Mn |
| Mar 31, 2024 | -16.60 Mn |
| Dec 31, 2023 | -20.56 Mn |
| Sep 30, 2023 | -16.63 Mn |
| Jun 30, 2023 | -13.85 Mn |
| Mar 31, 2023 | -13.33 Mn |
| Dec 31, 2022 | -12.85 Mn |
| Sep 30, 2022 | -9.30 Mn |
| Jun 30, 2022 | -15.13 Mn |
| Mar 31, 2022 | -12.87 Mn |
| Dec 31, 2021 | -7.83 Mn |
| Sep 30, 2021 | -16.78 Mn |